AMED iD3 Booster and DISC: Promoting drug discovery in academia

DOI
  • Chikazawa Kazuhiko
    Department of Innovative Drug Discovery and Development, Japan Agency for Medical Research and Development（AMED）
  • Terasaka Tadashi
    Department of Innovative Drug Discovery and Development, Japan Agency for Medical Research and Development（AMED）
  • Tokui Taro
    Daiichi Sankyo RD Novare Co., Ltd.

Bibliographic Information

Other Title
  • アカデミア創薬を牽引するAMED創薬ブースターとDISCについて

Search this article

Abstract

<p>The Department of Innovative Drug Discovery and Development (iD3) of AMED established Drug-Discovery Innovation and Screening Consortium (DISC) to accelerate the practical application of academic drug discovery research and bridge to pharmaceutical companies in 2015. DISC is an industry-academia open innovation initiative based on provided industry-original compound libraries from 22 pharmaceutical companies and high throughput screening (HTS). This program has many benefits for academia, for example, comprehensive drug discovery support (iD3 Booster), utilization of practical large-scale library and cutting-edge HTS equipment funded by AMED, and provision of licensing opportunities to pharmaceutical companies. In recent years, various improvements (DISC library expansion etc.) have been made. We hope that academia research will lead to breakthrough new drugs utilizing DISC.</p>

Journal

  • MEDCHEM NEWS

    MEDCHEM NEWS 30 (4), 162-170, 2020-11-01

    The Pharmaceutical Society of Japan

Keywords

Details 詳細情報について

Report a problem

Back to top